

November 19, 2003

Public Relations

Ono Pharmaceutical Co., Ltd.

Tel: +81-6-6263-5670

Fax: +81-6-6263-2950

Ono and Dong-A Signed a License Agreement on Elaspol[®] 100 for Injection for Acute Lung Injury

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka City, President: Kimiichiro Matsumoto) announced that the company has signed a license agreement with Dong-A Pharmaceutical Co., Ltd. (Headquarters: Seoul, Korea, President: Moon Seok Kang) to develop and market Elaspol[®] 100 for Injection, a drug for acute lung injury, in Korea.

Under the terms of the agreement, Dong-A is granted an exclusive license to develop and market the product in Korea. Dong-A will strive for launching the product in the beginning of 2005. Ono will manufacture and supply the product in vials to Dong-A.

Elaspol[®] 100 for Injection is a novel therapeutic agent for acute lung injury developed by Ono. In Japan, it was approved in April and its marketing started in June 2002 for the indication of acute lung injury associated with systemic inflammatory response syndrome.